Study of APH-1105 in Patients With Mild to Moderate Alzheimer's Disease
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2 study assessing the safety, tolerability and efficacy of intranasal
delivery of APH-1105 for the treatment of mild to moderate Alzheimer's in adult.